Eli Lilly Grants Early Access to Revolutionary Weight-Loss Drug Retatrutide
On August 3, 2026, pharmaceutical titan Eli Lilly announced an early access program for its experimental obesity drug, Retatrutide. This move comes ahead of the drug’s U.S. FDA approval, marking a significant expansion from a single compassionate-use case granted to a 79-year-old patient earlier this year. The decision was made following numerous reports of physicians not receiving responses from Lilly regarding requests for their patients.
Retatrutide is engineered to engage three hormonal pathways simultaneously – GLP-1, GIP, and glucagon. This makes it more potent than Lilly’s existing blockbuster weight-loss drug Zepbound (which targets two) and Novo Nordisk’s Wegovy (which targets one). In late-stage trials, patients on the highest 12 mg dose lost an average of 28.3% of their body weight over 80 weeks. These results are comparable to those of bariatric surgery.
To qualify for the expanded access program, patients must meet the following criteria:
- Be at least 18 years old
- Have refractory obesity despite tolerating the highest approved dose of obesity therapy
- Have at least two serious or life-threatening obesity-related complications
Lilly plans to file for FDA approval of Retatrutide in the first quarter of 2027.
Source: Quartz – Eli Lilly expanding early access to Retatrutide weight loss drug (August 4, 2026)